Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Snr Appt at Geomerics

16 Dec 2005 14:32

Angle PLC16 December 2005 For Immediate Release 16 December 2005 ANGLE plc ("ANGLE" or the "Company") SENIOR APPOINTMENT; GEOMERICS LTD ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce the appointment of Julian Davis, as Chief TechnologyOfficer at venture company, Geomerics Ltd. Davis, who joins from Kuju Entertainment, the publicly listed computer gamescompany where he held the position of Technical Director for the past six years,has been an active participant on the Microsoft Graphics and Xbox advisoryboards and is highly regarded for his videogame industry knowledge andexperience. Commenting on his appointment, Davis said: "I am delighted to be joining Geomerics. I am confident that the technology willrevolutionise the way video games are made and will offer substantial advantagesand benefits to developers and publishers of next generation titles." Dr Chris Doran, CEO of Geomerics added, "There is no doubt that Julian is an industry heavyweight and will be a valuableasset to us. Geomerics' technology is advancing quickly and we are confident ithas the capacity to greatly impact this industry in the near future. Julian'sexperience and advice will be invaluable in our drive towards commercialisation.We are truly excited to have him on board." Founded earlier this year, Geomerics has secured intellectual property in the field of geometric algebra, a powerful new form of mathematics that vastly simplifies complex geometric calculations. Geometric algebra has its origins in the rather esoteric academic discipline of theoretical cosmology, but it has nowbeen developed for application in a wide variety of disparate commercial applications such as computer graphics in computer games and electromagnetic modelling which is used, amongst other things, for optimising the design of mobile phone antennas and reducing the radar signature of ships and planes. Geomerics' technology provides a major step-change improvement over thecompetition, and is set to revolutionise the market. Overall the market forcomputer games is currently worth more than $30bn and growing rapidly, and themarket for graphics within these games is worth over $600m per year. Since itsestablishment, Geomerics has developed a suite of impressive demonstrationswhich have attracted considerable interest in early customer meetings. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director - New Ventures Geomerics Ltd 01223 370030Dr Chris Doran, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.